Oncogene-addicted NSCLC: Highlights from ASCO 2024

Prof. Nicolas Girard joined us at ASCO 2024 to share his views on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at the congress. 

Prof. Girard reviewed data from the following studies:

• LBA8505 - Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced NSCLC: Primary results, including overall survival, from the global, phase 3, randomised controlled PALOMA-3 trial
• LBA8612 - Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced NSCLC: Results from the phase 2 PALOMA-2 study
• LBA8503 - Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ NSCLC: 5-year progression-free survival and safety from the CROWN study
• LBA8509 - KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic NSCLC harbouring a KRAS^G12C mutation
• LBA8593 - Safety and anti-tumour activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase 1/2 study
• Abstract 8514 - Phase 1a/1b trial of zongertinib (BI 1810631), a HER2-specific TKI, in patients with HER2 aberration-positive solid tumours: Updated Phase 1a data from Beamion LUNG-1, including progression-free survival data

Watch the short video update and download the accompanying slides to see the key data from these trials.

Clinical Takeaways

EGFR:

• PALOMA-2: provides evidence for the efficacy and safety of subcutaneous amivantamab + lazertinib and suggests it could be suitable as a first-line option for patients with EGFR-mutant advanced NSCLC
• PALOMA-3: subcutaneous amivantamab with lazertinib is noninferior to intravenous amivantamab plus lazertinib and has an improved safety profile and greater convenience

ALK:

• CROWN: after 5 years of treatment, the median PFS of patients with advanced ALK-positive NSCLC treated with lorlatinib has yet to be reached, corresponding with the longest PFS ever reported in advanced NSCLC

KRAS:

• KRYSTAL-12: adagrasib demonstrated a statistically significant and clinically meaningful improvement in PFS and ORR over docetaxel in patients with previously treated KRASG12C-mutated NSCLC

HER2:

• SOHO-01: in patients with heavily pre-treated HER2-mutant NSCLC, treatment with BAY 2927088 resulted in rapid, substantial and durable responses
• Beamion LUNG-1: zongertinib was well tolerated and demonstrated promising initial efficacy in pre-treated patients with HER2-mutated NSCLC